Quince Therapeutics S.p.A.
- Address
- Via Antonio Meucci 3
Sponsor Overview
Specializations
Ataxia Telangiectasia
Quince Therapeutics S.p.A. focuses its clinical research on Ataxia Telangiectasia and the associated neurological burden of this rare genetic disorder, with particular attention to central nervous system symptoms and functional impairment in children.
- CNS symptoms
- Neurological dysfunction
- Rare disease care
The sponsor’s research activity in this area is directed toward understanding and addressing the motor and neurological manifestations of Ataxia Telangiectasia.
Neurology
The clinical portfolio places strong emphasis on neurology, especially measures of disease-related movement and coordination deficits, with outcomes centered on changes in neurological performance and symptom burden.
- Motor coordination
- Neurological assessment
- Functional impairment
This area reflects an interest in therapies aimed at improving everyday neurological function in patients affected by progressive central nervous system involvement.
Pediatric rare disease
Quince Therapeutics S.p.A. is active in pediatric rare disease research, with studies involving young participants and a focus on age-specific disease expression in Ataxia Telangiectasia.
- Pediatric patients
- Rare neurological disorders
- Childhood-onset disease
The sponsor’s clinical interest includes the needs of children living with chronic, disabling neurogenetic conditions.
Safety and tolerability
Alongside therapeutic effect, the sponsor’s trials address safety and tolerability in Ataxia Telangiectasia, supporting evaluation of treatment use in a vulnerable patient population.
- Safety monitoring
- Tolerability
- Long-term treatment use
Its research landscape also includes extension-focused clinical activity in neurological rare disease management.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of Neurological Effects of Dexamethasone Sodium Phosphate Encapsulated in Autologous Erythrocytes in Pediatric Ataxia Telangiectasia: A Randomized, Double-Blind, Placebo-Controlled Trial |  Belgium Denmark Germany Italy Norway Poland Spain | Not Recruiting |
| Open-Label Extension Study of Dexamethasone Sodium Phosphate in Patients with Ataxia Telangiectasia Following IEDAT-04-2022 Participation | Denmark Germany Italy Norway Poland Spain | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 13 sites across their trial portfolio.
Therapeutic Focus
- 1.Congenital, Hereditary, and Neonatal Diseases and Abnormalities2 trials165 other sponsors
- 2.Nervous System Diseases2 trials449 other sponsors
Partnered Research Centres
13 centres- Address
- Paseo De La Castellana 261, 28046 Madrid
- Address
- Theodor-Stern-Kai 7, 60590 Frankfurt
- Address
- Passeig De La Vall D'Hebron 119-129, 08035 Barcelona
- Address
- Haifa-Allee 24, Bretzenheim, 55128 Frankfurt
- Address
- Aleja Dzieci Polskich 20, 04-730 Warsaw
- Address
- Herestraat 49, 3000 Leuven
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Quince Therapeutics S.p.A..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.